Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Fulcrum Therapeutics, Inc. - Common Stock (NQ:FULC)

2.880 +0.240 (+9.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fulcrum Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
A Preview Of Fulcrum Therapeutics's Earnings
Via Benzinga
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FULC
From Rosen Law Firm
Via Business Wire
NASDAQ:FULC Shareholder Alert: Lawsuit Alleges Securities Laws Violations by Fulcrum Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 05/10/2023 -- The Shareholders Foundation announced that an investor, who purchased shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC), filed a lawsuit over alleged... 
Via SBWire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fulcrum Therapeutics, Inc. (FULC)
From Glancy Prongay & Murray LLP
Via Business Wire
Looking Into Fulcrum Therapeutics's Return On Capital Employed
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fulcrum, adidas, and Spirit and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Fulcrum Therapeutics, Inc. (FULC) Class Action Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Fulcrum Therapeutics, Inc.
From Robbins LLP
Via Business Wire
Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fulcrum Therapeutics, Inc. (FULC)
From Law Offices of Howard G. Smith
Via Business Wire
FULCRUM THERAPEUTICS, INC. (NASDAQ: FULC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)
From Bernstein Liebhard LLP
Via GlobeNewswire
FULC INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FULC
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fulcrum, and adidas and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Fulcrum Therapeutics, Inc. (FULC) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
FULCRUM THERAPEUTICS, INC. (NASDAQ: FULC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)
From Bernstein Liebhard LLP
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Fulcrum Therapeutics, Inc. (FULC) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
FULC EQUITY ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – FULC
From Rosen Law Firm
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Fulcrum Therapeutics, Inc. (FULC) Investors
From Law Offices of Howard G. Smith
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
FULCRUM ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Fulcrum Therapeutics, Inc. (FULC)
From Robbins LLP
Via Business Wire
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Fulcrum Therapeutics Announces CFO Resignation
Rajavelu to continue supporting Fulcrum in a consulting capacity 
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
NASDAQ:FULC Shareholder Notice: Investigation over Possible Securities Laws Violations by Fulcrum Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 03/14/2023 -- Fulcrum Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023
Via Benzinga
United Airlines To Rally Around 54%? Here Are 10 Other Analyst Forecasts For Friday
Piper Sandler raised the price target for Riskified Ltd. (NYSE: RSKD) from $6 to $8. Piper Sandler analyst Brent Bracelin upgraded the stock from Neutral to Overweight. Riskified shares rose 2.4% to... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.